After the first half of the year, the pharmaceutical supplier Siegfried maintains its forecasts for the financial year 2026. Thanks to acquisitions, Zofinger will increase mainly in the second half of the year.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
After the first half of the year, the pharmaceutical supplier Siegfried maintains its forecasts for the financial year 2026. Thanks to acquisitions, Zofinger will increase mainly in the second half of the year.